Beta-Glucan Oligosaccharides Could Lower Cholesterol Levels - Thai Study

Why It Matters

The findings position β‑glucan oligosaccharides as a promising, low‑risk nutraceutical for lipid control, potentially reshaping supplement portfolios and informing future regulatory limits.

Key Takeaways

• Oligosaccharides cut total cholesterol and LDL after 12 weeks
• Lipid reduction persisted two weeks post‑supplementation for oligosaccharides
• Polysaccharides showed no sustained LDL improvement
• Oligosaccharides caused fewer bowel‑movement side effects than polysaccharides
• 2000 mg daily dose deemed safe for healthy adults

Pulse Analysis

Beta‑glucans have long been touted for their soluble‑fiber benefits, yet most research focuses on high‑molecular‑weight polysaccharides derived from yeast or oats. The Thai study breaks new ground by isolating β‑1,3/1,6‑glucan oligosaccharides through gamma irradiation of *Ophiocordyceps dipterigena* fermentation products, creating a low‑molecular‑weight variant that appears more bioactive. By directly comparing these oligosaccharides with their larger polysaccharide counterparts in a double‑blind, placebo‑controlled design, the researchers provide the first head‑to‑head efficacy data, highlighting a distinct lipid‑lowering advantage.

Over the 12‑week intervention, participants taking the oligosaccharide capsules experienced a statistically significant drop in total cholesterol and LDL, with the LDL benefit persisting for two weeks after cessation. In contrast, the polysaccharide group’s LDL levels reverted to baseline, underscoring the importance of molecular size in cholesterol modulation. Safety metrics were uniformly reassuring across both arms, but the oligosaccharide cohort reported fewer bowel‑movement disturbances, suggesting a more tolerable gastrointestinal profile—a critical factor for consumer adherence in the nutraceutical market.

Regulatory implications are equally compelling. The European Food Safety Authority currently caps yeast‑derived β‑glucan polysaccharides at 375 mg/day for supplements, yet this trial demonstrates that 2 g of the oligosaccharide form is well tolerated in healthy adults. This gap may prompt agencies to revisit acceptable daily intake thresholds for novel fungal glucans. As cardiovascular disease remains a leading health burden, the demonstrated lipid‑lowering efficacy of β‑glucan oligosaccharides could fuel new product pipelines and inspire larger, outcome‑focused trials to validate clinical benefits beyond surrogate lipid markers.